» Articles » PMID: 38026088

Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy Versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis

Overview
Publisher Dove Medical Press
Date 2023 Nov 29
PMID 38026088
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: This study aimed to compare the efficacy and safety of neoadjuvant chemotherapy (NCT) and neoadjuvant immunotherapy combined with chemotherapy (NICT) combined with radical lung cancer resection for the treatment of patients with resectable non-small cell lung cancer (NSCLC). To adjust for confounding factors, we innovatively adopted two matching methods: propensity score (PS) and inverse probability of treatment weighting (IPTW).

Patients And Methods: We conducted a retrospective analysis of the clinicopathological features and prognosis of patients with resectable NSCLC treated with NCT or NICT combined with radical lung cancer resection using propensity score matching (PSM) at a ratio of 1:1 and IPTW to balance potential bias.

Results: After PSM, 116 pairs of patients who had undergone NCT or NICT were selected for the final analysis. The pathological complete remission (pCR) and major pathological remission (MPR) rates were significantly better in the NICT group than in the NCT group (pCR rate of 44.8% vs 2.6%, < 0.001; MPR rate of 66.4% vs 20.7%, < 0.001). No significant difference was seen between the NICT and NCT groups in terms of postoperative complications (12.1% vs 9.5%, =0.182). Patients in the NICT group had significantly better disease-free survival (DFS) and overall survival(OS) than those in the NCT group ([3-year DFS: 75.2% vs 43.3%, < 0.001] and [3-year OS: 91.5% vs 58.0%, < 0.001]). Among all patients, those with postoperative pathology of pCR had better DFS (< 0.001) and OS (= 0.009). Patients with postoperative pathology of MPR had better DFS (< 0.001) and OS (< 0.001). The IPTW method yielded similar pathologic and prognostic results.

Conclusion: Patients with resectable NSCLC treated with NICT had better pathological responses and prognosis, than those treated with NCT, and the safety profiles of NICT and NCT were similar.

Citing Articles

Whole slide image-based weakly supervised deep learning for predicting major pathological response in non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a multicenter, retrospective, cohort study.

Han D, Li H, Zheng X, Fu S, Wei R, Zhao Q Front Immunol. 2024; 15:1453232.

PMID: 39372403 PMC: 11449764. DOI: 10.3389/fimmu.2024.1453232.


Non-invasive multimodal CT deep learning biomarker to predict pathological complete response of non-small cell lung cancer following neoadjuvant immunochemotherapy: a multicenter study.

Ye G, Wu G, Qi Y, Li K, Wang M, Zhang C J Immunother Cancer. 2024; 12(9).

PMID: 39231545 PMC: 11409329. DOI: 10.1136/jitc-2024-009348.


CT-based quantification of intratumoral heterogeneity for predicting pathologic complete response to neoadjuvant immunochemotherapy in non-small cell lung cancer.

Ye G, Wu G, Zhang C, Wang M, Liu H, Song E Front Immunol. 2024; 15:1414954.

PMID: 38933281 PMC: 11199789. DOI: 10.3389/fimmu.2024.1414954.


Perioperative immunotherapy for stage II-III non-small cell lung cancer: a meta-analysis base on randomized controlled trials.

Yu A, Fu F, Li X, Wu M, Yu M, Zhang W Front Oncol. 2024; 14:1351359.

PMID: 38454928 PMC: 10917905. DOI: 10.3389/fonc.2024.1351359.

References
1.
Wang J, Li J, Cai L, Chen S, Jiang Y . The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer. Ann Transl Med. 2021; 9(6):486. PMC: 8039669. DOI: 10.21037/atm-21-670. View

2.
Nagai K, Tsuchiya R, Mori T, Tada H, Ichinose Y, Koike T . A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg. 2003; 125(2):254-60. DOI: 10.1067/mtc.2003.15. View

3.
Reck M, Remon J, Hellmann M . First-Line Immunotherapy for Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(6):586-597. DOI: 10.1200/JCO.21.01497. View

4.
Uprety D, Mandrekar S, Wigle D, Roden A, Adjei A . Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches. J Thorac Oncol. 2020; 15(8):1281-1297. DOI: 10.1016/j.jtho.2020.05.020. View

5.
Reuss J, Anagnostou V, Cottrell T, Smith K, Verde F, Zahurak M . Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer. 2020; 8(2). PMC: 7488786. DOI: 10.1136/jitc-2020-001282. View